WO1999056738A1 - Utilisation de triclosan pour traiter des infections par helicobacter pylori - Google Patents

Utilisation de triclosan pour traiter des infections par helicobacter pylori Download PDF

Info

Publication number
WO1999056738A1
WO1999056738A1 PCT/GB1999/001188 GB9901188W WO9956738A1 WO 1999056738 A1 WO1999056738 A1 WO 1999056738A1 GB 9901188 W GB9901188 W GB 9901188W WO 9956738 A1 WO9956738 A1 WO 9956738A1
Authority
WO
WIPO (PCT)
Prior art keywords
triclosan
medicament
treatment
pylori infections
patient
Prior art date
Application number
PCT/GB1999/001188
Other languages
English (en)
Inventor
Peter William Dettmar
Original Assignee
Reckitt & Colman Products Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt & Colman Products Limited filed Critical Reckitt & Colman Products Limited
Priority to EP99919357A priority Critical patent/EP1075257A1/fr
Priority to AU37162/99A priority patent/AU749509B2/en
Publication of WO1999056738A1 publication Critical patent/WO1999056738A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen

Definitions

  • This invention relates to the preparation of medicaments for the treatment of gastrointestinal disorders associated with Helicobacter pylori infections.
  • H. pylori infections have now been acknowledged to be associated with a wide range of gastrointestinal disorders, including gastritis and peptic ulcer disease.
  • a wide variety of treatments have been proposed for H. pylori associated gastric disorders, including the use of bismuth salts, antiinfective agents or H2 -receptor antagonists; most of which procedures have afforded limited success. Combinations of some or all of these agents have been used and have sometimes demonstrated greater effect.
  • the problems of using such combination products are well known (eg poor compliance) .
  • GB 2243549 it is suggested that doses of up to 200 mg of triclosan may be suitable for the treatment of H. pylori associated gastrointestinal disorders. Whilst such doses have been shown to be effective in vivo we have now surprisingly found that much higher doses may be significantly more effective.
  • H. pylori infections The major site of H. pylori infections in man is believed to be at the interface of the adherent gastric mucus layer and the gastric mucosa .
  • triclosan is primarily delivered to such sites of infection is direct (i.e. by diffusion through the mucus layer) rather than indirectly by systemic delivery (as is believed to be the case for antibiotic treatments) .
  • the amount of triclosan that can reach the site of infection is controlled by the amount that can pass into the mucus layer from the stomach contents.
  • WO95/08332 discloses administering from 50 mg to 2000 mg of a diphenyl ether phosphate ester of triclosan for the treatment of gastrointestineal disorders due to H. pylori infection.
  • the triclosan phosphate is more soluble than triclosan and is thus cable of passing into the mucus layer quicker and to a greater extent than triclosan.
  • triclosan phosphate lacks biological efficacy in that it is not active until the ester is hydrolysed off the triclosan, a reaction which is enzyme controlled and occurs within the bacterium.
  • Triclosan is less soluble than triclosan phosphate in conditions as acidic as those in the stomach (triclosan has a solubility of approximately 10 micrograms/ml at pH's below 7), and high doses were expected to be of little added value because the solubility limit would soon be passed. That is, once the stomach contents were saturated with triclosan any further material would remain in suspension and not be available to pass into the mucus . Such suspended material would not remain in the stomach long because of its regular emptying and so would not contribute to the activity of the dissolved material. Thus the fact that doses well above the solubility limit of triclosan in normal stomach contents show an increase in activity is highly unexpected.
  • the undissolved triclosan is preferentially taken up into the adherent mucus layer coating the stomach walls and forms depots there, allowing a much higher proportion of the actual triclosan molecules to be delivered directly to the site of infection.
  • the dose which is delivered is biologically active i.e. it does not require any enzyme activity to become activated and is therefore not dependant on prevailing conditions for its efficacy.
  • triclosan for the preparation of a medicament for the treatment of gastrointestinal disorders associated with Helicobacter pylori infections, characterised in that the medicament is in oral unit dosage form, each unit dose comprising 300 mg to 2000 mg of triclosan.
  • a medicament in oral unit dosage form comprising from 300 mg to 2000 mg of triclosan and a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier is one which is suitable for oral ingestion and which is capable of delivering the triclosan to the upper gastrointestinal tract, preferably the stomach.
  • Such carriers therefore include carbomer, e.g. Carbopol (RTM) and microcrystalline cellulose e.g. Avicel (RTM) .
  • the amount of carrier present in the medicament is sufficient to provide an effective quantity for administration of the medicament and is preferably from 50 mg to 2000 mg per unit dose .
  • each unit dose will comprise from 300 mg to 1000 mg and most preferably 400 mg to 800 mg of triclosan.
  • Dosing frequency will be preferably from once to four times daily, most preferably twice or three times daily. Accordingly, a patient may receive anything from 300 mg to 8000 mg triclosan in a 24 hour period. Duration of the dosing regimen will be preferably from about 7 to about 56 days, more preferably from 7 to 28, most preferably from 7 to 21 days.
  • Oral unit dosage forms of triclosan include any forms that can be conveniently administered to a patient to deliver a fixed dose. Such forms include tablets, capsules (both hard and soft), and sachets containing granules, powders or liquids. They also include sustained release forms .
  • the dosage forms may further comprise any conventional suitable excipients depending upon their form; for example, fillers, binding agents, flavours, lubricants, mucoadhesive polymers etc .
  • the dosage forms may be produced by any conventional means, with the proviso that the process does not result in significant triclosan losses .
  • Carbopol 974P (Goodrich) 100 66.7 Avicel PH200 (FMC Company) 210 140 Calcium carbonate 100 66.7 Sodium Crosscarmellose 36 24 Magnesium stearate 4 2.6
  • magnesium stearate All the ingredients except the magnesium stearate are blended for 10 minutes in a high speed food processor.
  • the magnesium stearate is added and blended in for 2 minutes using a tumble mixer.
  • the blended powders are compressed into 750 mg caplet shaped tablets .
  • Tablets are prepared as in Example 1 .
  • Example 4 Tablets are prepared as in Example 1 but are compressed into 1000 mg caplets .
  • Example 4
  • the polyethylene glycol 1000 is melted at 60°C and the triclosan is stirred in and dispersed.
  • the liquid mixture is filled into hard gelatin capsules (size 0) to a fill weight of 750 mg and solidified by cooling.
  • Tablets are prepared as in Example 1 but are compressed into 1000 mg caplets.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation du triclosan dans la préparation d'un médicament destiné au traitement de troubles gastro-intestinaux associés aux infections par Helicobacter pylori. Elle est caractérisée en ce que le médicament se présente sous la forme d'une dose unitaire orale, chaque dose unitaire comprenant entre 300 et 2000 mg de triclosan.
PCT/GB1999/001188 1998-05-05 1999-05-05 Utilisation de triclosan pour traiter des infections par helicobacter pylori WO1999056738A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP99919357A EP1075257A1 (fr) 1998-05-05 1999-05-05 Utilisation de triclosan pour traiter des infections par helicobacter pylori
AU37162/99A AU749509B2 (en) 1998-05-05 1999-05-05 Use of triclosan for the treatment of helicobacter pylori infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9809347.9A GB9809347D0 (en) 1998-05-05 1998-05-05 Compositions
GB9809347.9 1998-05-05

Publications (1)

Publication Number Publication Date
WO1999056738A1 true WO1999056738A1 (fr) 1999-11-11

Family

ID=10831308

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/001188 WO1999056738A1 (fr) 1998-05-05 1999-05-05 Utilisation de triclosan pour traiter des infections par helicobacter pylori

Country Status (4)

Country Link
EP (1) EP1075257A1 (fr)
AU (1) AU749509B2 (fr)
GB (2) GB9809347D0 (fr)
WO (1) WO1999056738A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432949B1 (en) 1998-08-04 2002-08-13 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines
US6465455B1 (en) 1998-05-15 2002-10-15 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
US6498274B1 (en) 1997-09-23 2002-12-24 Zeneca Limited Amide derivatives for the treatment of diseases mediated by cytokines
US6821965B1 (en) 1998-08-04 2004-11-23 Asterzeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629477A (en) * 1966-08-08 1971-12-21 Geigy Chem Corp Halogenated diphenyether-containing compositions and control of pests therewith
EP0455475A2 (fr) * 1990-05-03 1991-11-06 Reckitt And Colman Products Limited Utilisation de triclosan pour traiter les affections du canal digestif
WO1995008332A1 (fr) * 1993-09-20 1995-03-30 The Procter & Gamble Company Utilisation de phosphates de triclosan dans le traitement de troubles gastrointestinaux dus a l'infection a heliobacter
WO1996000569A1 (fr) * 1994-06-29 1996-01-11 Reckitt & Colman Products Limited Compositions pharmaceutiques renfermant du triclosan ou ses derives et de l'edta ou de l'egta
WO1996028141A1 (fr) * 1995-03-13 1996-09-19 Reckitt & Colman Products Limited Ameliorations concernant des compositions organiques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629477A (en) * 1966-08-08 1971-12-21 Geigy Chem Corp Halogenated diphenyether-containing compositions and control of pests therewith
EP0455475A2 (fr) * 1990-05-03 1991-11-06 Reckitt And Colman Products Limited Utilisation de triclosan pour traiter les affections du canal digestif
WO1995008332A1 (fr) * 1993-09-20 1995-03-30 The Procter & Gamble Company Utilisation de phosphates de triclosan dans le traitement de troubles gastrointestinaux dus a l'infection a heliobacter
WO1996000569A1 (fr) * 1994-06-29 1996-01-11 Reckitt & Colman Products Limited Compositions pharmaceutiques renfermant du triclosan ou ses derives et de l'edta ou de l'egta
WO1996028141A1 (fr) * 1995-03-13 1996-09-19 Reckitt & Colman Products Limited Ameliorations concernant des compositions organiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Triclosan phosphates for the treatment of gastrointestinal disorders due to Helicobacter infection.", EXPERT OPINION ON THERAPEUTIC PATENTS, (1995) 5/10 (1107-1109)., XP002113724 *
CATRENICH, C. E. ET AL: "Clinical relevance of bactericidal kinetics of antimicrobials directed against Helicobacter pylori.", GASTROENTEROLOGY, (1994) VOL. 106, NO. 4 SUPPL., PP. A61. MEETING INFO.: 95TH ANNUAL MEETING OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION NEW ORLEANS, LOUISIANA, USA MAY 15-18, 1994, XP002113725 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
US6498274B1 (en) 1997-09-23 2002-12-24 Zeneca Limited Amide derivatives for the treatment of diseases mediated by cytokines
US6686467B2 (en) 1997-09-23 2004-02-03 Zeneca Limited Amide derivatives for the treatment of diseases mediated by cytokines
US6465455B1 (en) 1998-05-15 2002-10-15 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
US6432949B1 (en) 1998-08-04 2002-08-13 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines
US6821965B1 (en) 1998-08-04 2004-11-23 Asterzeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors

Also Published As

Publication number Publication date
GB9910316D0 (en) 1999-06-30
EP1075257A1 (fr) 2001-02-14
AU749509B2 (en) 2002-06-27
GB2336999A (en) 1999-11-10
GB9809347D0 (en) 1998-07-01
AU3716299A (en) 1999-11-23

Similar Documents

Publication Publication Date Title
US4965252A (en) Cholesterol-lowering combination compositions of guar gum and niacin
CA2074215C (fr) Formulations orales ameliorees de nucleosides a base de dideoxypurine
US20080200549A1 (en) Pharmaceutical composition of ibuprofen and paracetamol and methods of using the same
JPH05112445A (ja) 作用開始を速くし潜在特性を増加させる移送システム
MY125662A (en) Pharmaceutical formulations containing darifenacin
WO1995020953A1 (fr) Agents therapeutiques contenant des hormones thyroidiennes
JPS63290830A (ja) 胃腸疾患を治療するための組成物及び方法
EP0211946B1 (fr) Chlorure de potassium a liberation controlee
AP324A (en) Medicaments for treating inflammatory conditions or for analgiesia.
US4888343A (en) Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process
IL106743A (en) Tablets with enhanced bioavailability of claudonic acid
JP2704721B2 (ja) イブプロフエン製剤
WO1999056738A1 (fr) Utilisation de triclosan pour traiter des infections par helicobacter pylori
US5035898A (en) Potassium/magnesium supplement
JPH0140009B2 (fr)
JP2511577B2 (ja) アルギン酸プロピレングリコ―ルエステルからなる徐放性製剤
US5155105A (en) Pharmaceutical methods for relief of dysmenorrhea and/or premenstrual syndrome and process
EP0261693A1 (fr) Régulateur de lipides traité
US4515802A (en) Analgesic preparations
CZ79593A3 (en) Antitussive preparation
CN108992456B (zh) 含有香叶木苷硫酸酯衍生物的药物组合物及其应用
JP2584636B2 (ja) 胃炎治療剤
JP4614638B2 (ja) 鎮痛剤組成物
JP2000344665A (ja) 鎮痛剤
WO2000021534A1 (fr) Combinaison pharmaceutique d'ibuprofene-lysine et de domperidone pour traiter la migraine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999919357

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 37162/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999919357

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 1999919357

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999919357

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 37162/99

Country of ref document: AU